LU85823A1 - Nouvelles combinaisons de medicaments ayant un effet synergique et procede pour les preparer - Google Patents

Nouvelles combinaisons de medicaments ayant un effet synergique et procede pour les preparer Download PDF

Info

Publication number: LU85823A1
Authority: LU; Luxembourg
Prior art keywords: antibiotic; composition according; treatment; weight ratio; composition
Prior art date: 1984-03-28

Application number

LU85823A

Other languages

English (en)

French (fr)

Inventor

Janos Varga

Ferenc Simon

Attila Romvary

Laszlo Bozzay

Edit Brueckner

Original Assignee

Hajdusagi Agraripari Egyesules

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-03-28

Filing date

1985-03-28

Publication date

1986-10-06

1984-03-28 Priority claimed from HU122584A external-priority patent/HU191399B/hu

1984-03-28 Priority claimed from HU122684A external-priority patent/HU190952B/hu

1984-04-20 Priority claimed from HU152784A external-priority patent/HU190958B/hu

1985-03-28 Application filed by Hajdusagi Agraripari Egyesules filed Critical Hajdusagi Agraripari Egyesules

1986-10-06 Publication of LU85823A1 publication Critical patent/LU85823A1/fr

Links

230000002195 synergetic effect Effects 0.000 title claims description 8
239000000890 drug combination Substances 0.000 title description 3
238000004519 manufacturing process Methods 0.000 title 1
239000003242 anti bacterial agent Substances 0.000 claims description 14
230000003115 biocidal effect Effects 0.000 claims description 14
238000002360 preparation method Methods 0.000 claims description 14
239000002253 acid Substances 0.000 claims description 13
239000000203 mixture Substances 0.000 claims description 12
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims description 12
241001465754 Metazoa Species 0.000 claims description 10
229940126575 aminoglycoside Drugs 0.000 claims description 10
229930193140 Neomycin Natural products 0.000 claims description 8
229950006334 apramycin Drugs 0.000 claims description 8
XZNUGFQTQHRASN-XQENGBIVSA-N apramycin Chemical compound O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O XZNUGFQTQHRASN-XQENGBIVSA-N 0.000 claims description 8
208000004396 mastitis Diseases 0.000 claims description 8
229960004927 neomycin Drugs 0.000 claims description 8
230000037396 body weight Effects 0.000 claims description 7
210000000481 breast Anatomy 0.000 claims description 7
239000008267 milk Substances 0.000 claims description 7
210000004080 milk Anatomy 0.000 claims description 7
235000013336 milk Nutrition 0.000 claims description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 6
230000000241 respiratory effect Effects 0.000 claims description 6
229960005322 streptomycin Drugs 0.000 claims description 6
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 6
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
229930182566 Gentamicin Natural products 0.000 claims description 5
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 5
206010040047 Sepsis Diseases 0.000 claims description 5
229960000318 kanamycin Drugs 0.000 claims description 5
229930027917 kanamycin Natural products 0.000 claims description 5
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 5
229930182823 kanamycin A Natural products 0.000 claims description 5
238000000034 method Methods 0.000 claims description 5
229960000268 spectinomycin Drugs 0.000 claims description 5
UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims description 5
229960000707 tobramycin Drugs 0.000 claims description 5
208000013223 septicemia Diseases 0.000 claims description 4
206010057190 Respiratory tract infections Diseases 0.000 claims description 3
239000004480 active ingredient Substances 0.000 claims description 3
231100000252 nontoxic Toxicity 0.000 claims description 3
230000003000 nontoxic effect Effects 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
208000019206 urinary tract infection Diseases 0.000 claims description 3
239000000969 carrier Substances 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims description 2
235000015112 vegetable and seed oil Nutrition 0.000 claims description 2
239000008158 vegetable oil Substances 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims 2
YXQXDXAHCSEVSD-GCYNEOGWSA-N dynamutilin Chemical compound OC(=O)\C=C\C(O)=O.CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 YXQXDXAHCSEVSD-GCYNEOGWSA-N 0.000 claims 2
239000007788 liquid Substances 0.000 claims 2
239000000843 powder Substances 0.000 claims 2
229940092292 tiamulin fumarate Drugs 0.000 claims 2
UURAUHCOJAIIRQ-QGLSALSOSA-N tiamulin Chemical compound CCN(CC)CCSCC(=O)O[C@@H]1C[C@@](C)(C=C)[C@@H](O)[C@H](C)[C@@]23CC[C@@H](C)[C@]1(C)[C@@H]2C(=O)CC3 UURAUHCOJAIIRQ-QGLSALSOSA-N 0.000 description 15
229960004885 tiamulin Drugs 0.000 description 14
229940088710 antibiotic agent Drugs 0.000 description 12
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 10
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
241000283690 Bos taurus Species 0.000 description 5
206010012735 Diarrhoea Diseases 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
241000282887 Suidae Species 0.000 description 5
244000144977 poultry Species 0.000 description 5
241000204031 Mycoplasma Species 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
239000013256 coordination polymer Substances 0.000 description 4
201000010099 disease Diseases 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
244000052769 pathogen Species 0.000 description 4
241000606860 Pasteurella Species 0.000 description 3
241000589516 Pseudomonas Species 0.000 description 3
241000607142 Salmonella Species 0.000 description 3
241000191940 Staphylococcus Species 0.000 description 3
241000282898 Sus scrofa Species 0.000 description 3
206010046793 Uterine inflammation Diseases 0.000 description 3
229940126574 aminoglycoside antibiotic Drugs 0.000 description 3
239000002647 aminoglycoside antibiotic agent Substances 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
235000020188 drinking water Nutrition 0.000 description 3
239000003651 drinking water Substances 0.000 description 3
208000001848 dysentery Diseases 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
230000002906 microbiologic effect Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894006 Bacteria Species 0.000 description 2
241000589893 Brachyspira hyodysenteriae Species 0.000 description 2
241000186216 Corynebacterium Species 0.000 description 2
235000014066 European mistletoe Nutrition 0.000 description 2
241000588748 Klebsiella Species 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
206010035664 Pneumonia Diseases 0.000 description 2
241000588769 Proteus <enterobacteria> Species 0.000 description 2
235000012300 Rhipsalis cassutha Nutrition 0.000 description 2
241000221012 Viscum Species 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
244000309466 calf Species 0.000 description 2
235000013365 dairy product Nutrition 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
210000002219 extraembryonic membrane Anatomy 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
241000894007 species Species 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
ZEUUPKVZFKBXPW-TWDWGCDDSA-N (2s,3r,4s,5s,6r)-4-amino-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,5s,6r)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N ZEUUPKVZFKBXPW-TWDWGCDDSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
WGLYHYWDYPSNPF-RQFIXDHTSA-N Apramycin sulfate Chemical compound OS(O)(=O)=O.O([C@H]1O[C@@H]2[C@H](O)[C@@H]([C@H](O[C@H]2C[C@H]1N)O[C@@H]1[C@@H]([C@@H](O)[C@H](N)[C@@H](CO)O1)O)NC)[C@@H]1[C@@H](N)C[C@@H](N)[C@H](O)[C@H]1O WGLYHYWDYPSNPF-RQFIXDHTSA-N 0.000 description 1
208000037157 Azotemia Diseases 0.000 description 1
241000588807 Bordetella Species 0.000 description 1
201000004813 Bronchopneumonia Diseases 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010008631 Cholera Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
101710200114 Cysteine proteinase inhibitor 10 Proteins 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
208000005577 Gastroenteritis Diseases 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
206010024641 Listeriosis Diseases 0.000 description 1
241000204045 Mycoplasma hyopneumoniae Species 0.000 description 1
206010028470 Mycoplasma infections Diseases 0.000 description 1
239000004104 Oleandomycin Substances 0.000 description 1
RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 description 1
206010030302 Oliguria Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000004100 Oxytetracycline Substances 0.000 description 1
206010034107 Pasteurella infections Diseases 0.000 description 1
241001494479 Pecora Species 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000018569 Respiratory Tract disease Diseases 0.000 description 1
244000292604 Salvia columbariae Species 0.000 description 1
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
235000001498 Salvia hispanica Nutrition 0.000 description 1
206010039509 Scab Diseases 0.000 description 1
239000004187 Spiramycin Substances 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
241000191967 Staphylococcus aureus Species 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000589886 Treponema Species 0.000 description 1
239000004182 Tylosin Substances 0.000 description 1
229930194936 Tylosin Natural products 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
229940124339 anthelmintic agent Drugs 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
235000014167 chia Nutrition 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
OEBRKCOSUFCWJD-UHFFFAOYSA-N dichlorvos Chemical compound COP(=O)(OC)OC=C(Cl)Cl OEBRKCOSUFCWJD-UHFFFAOYSA-N 0.000 description 1
229950001327 dichlorvos Drugs 0.000 description 1
229960002222 dihydrostreptomycin Drugs 0.000 description 1
ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000003640 drug residue Substances 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
244000000058 gram-negative pathogen Species 0.000 description 1
244000000059 gram-positive pathogen Species 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
229960002064 kanamycin sulfate Drugs 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
229940041033 macrolides Drugs 0.000 description 1
-1 mercapto-acetoxyl Chemical group 0.000 description 1
229950011272 nebramycin Drugs 0.000 description 1
230000003589 nefrotoxic effect Effects 0.000 description 1
229940053050 neomycin sulfate Drugs 0.000 description 1
229960002351 oleandomycin Drugs 0.000 description 1
235000019367 oleandomycin Nutrition 0.000 description 1
RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960000625 oxytetracycline Drugs 0.000 description 1
235000019366 oxytetracycline Nutrition 0.000 description 1
IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
201000005115 pasteurellosis Diseases 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
229960002771 retapamulin Drugs 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229960001294 spiramycin Drugs 0.000 description 1
235000019372 spiramycin Nutrition 0.000 description 1
229930191512 spiramycin Natural products 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
238000004448 titration Methods 0.000 description 1
229960004477 tobramycin sulfate Drugs 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
229960004059 tylosin Drugs 0.000 description 1
235000019375 tylosin Nutrition 0.000 description 1
WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Polymers & Plastics (AREA)
Emergency Medicine (AREA)
Food Science & Technology (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Animal Husbandry (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

LU85823A 1984-03-28 1985-03-28 Nouvelles combinaisons de medicaments ayant un effet synergique et procede pour les preparer LU85823A1 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
HU122584A HU191399B (en)	1984-03-28	1984-03-28	Process for the production of new compound medicine of synergic effect
HU122684		1984-03-28
HU122584		1984-03-28
HU122684A HU190952B (en)	1984-03-28	1984-03-28	Process for the production of new compound medicines of syneric effect, suitable for treating ureteral, respiratory and other infections of domestic animals
HU152784		1984-04-20
HU152784A HU190958B (en)	1984-04-20	1984-04-20	Process for producing new pharmaceutical compositions of synergetic activity for treating infections of domestic animals by protozoa and bacteria

Publications (1)

Publication Number	Publication Date
LU85823A1 true LU85823A1 (fr)	1986-10-06

Family

ID=27269952

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85823A LU85823A1 (fr)	1984-03-28	1985-03-28	Nouvelles combinaisons de medicaments ayant un effet synergique et procede pour les preparer

Country Status (11)

Country	Link
US (1)	US4650790A (de)
AT (1)	AT388100B (de)
BE (1)	BE902010A (de)
CH (1)	CH664285A5 (de)
DE (1)	DE3511307A1 (de)
ES (1)	ES8607728A1 (de)
FR (1)	FR2561920B1 (de)
GB (1)	GB2159409B (de)
LU (1)	LU85823A1 (de)
NL (1)	NL8500928A (de)
SE (1)	SE8501532L (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU199682B (en) *	1988-04-01	1990-03-28	Egyt Gyogyszervegyeszeti Gyar	Process for producin synergetic veterinary composition
EP0585514B1 (de) *	1992-01-09	1998-10-07	LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d., Ljubljana	Tierfutter, Futterzusatz oder Trinkwasser, die eine antibiotischen Mischung von Gentamicin mit Lincomycin oder Clindamycin enthalten
DE69321554T2 (de) *	1992-11-08	1999-06-24	Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D., Ljubljana	Antibiotische Mischung von Gentamicin mit Lincomycin enthaltendes, veterinäres Präparat als Zusatzmittel für Trinkwasser oder Tierfutter und dessen Verwendung in der Aufzucht von Schweinen
US5534253A (en) *	1995-06-07	1996-07-09	Biogaia Ab	Method of treating enteropathogenic bacterial infections in poultry
FR2761074B1 (fr)	1997-03-24	1999-05-28	Exsymol Sa	Composes a base de silicium biologiquement actifs sous forme solide
RU2115418C1 (ru) *	1998-01-23	1998-07-20	Анатолий Владимирович Толстов	Комбинированное химиотерапевтическое средство "бутол" для лечения местной раневой инфекции и воспалительных заболеваний
US20100197727A1 (en) *	2005-06-28	2010-08-05	Koenraad Jozef Lodewijk Marcel Andries	Quinoline Derivatives as Antibacterial Agents
EP3551191A4 (de) *	2016-12-09	2020-09-09	EnBiotix, Inc.	Aminoglykosid-potenzierung zur behandlung von pulmonaler bakterieller infektion
EP3833329A1 (de) *	2018-08-06	2021-06-16	Khan, Khalid	Antimikrobielle formulierungen mit vancomycin oder tobramycin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2799620A (en) *	1956-06-29	1957-07-16	Rutgers Res And Educational Fo	Neomycin and process of preparation
US2931798A (en) *	1956-09-05	1960-04-05	Umezawa Hamao	Kanamycin and processes for the preparation thereof
BE756856A (fr) *	1969-09-30	1971-03-01	Chinoin Gyogyszer Es Vegyeszet	Compositions antibiotiques nouvelles possedant un effet therapeutique accru et leur preparation
CH551965A (de) *	1970-06-22	1974-07-31	Scherico Ltd	Verfahren zur herstellung antibiotisch wirksamer verbindungen.
US3987194A (en) *	1975-05-12	1976-10-19	E. R. Squibb & Sons, Inc.	Use of pleuromutilin derivatives for the treatment of swine dysentery
CH627940A5 (de) *	1976-12-23	1982-02-15	Sandoz Ag	Kokzidiostatisches kombinationspraeparat.
GB2072012B (en) *	1980-03-14	1984-07-25	Squibb & Sons Inc	Veterinary compositions containing pleuromutilin derivatives

1985
- 1985-03-25 BE BE1/011220A patent/BE902010A/fr not_active IP Right Cessation
- 1985-03-26 AT AT0089485A patent/AT388100B/de not_active IP Right Cessation
- 1985-03-27 GB GB08508000A patent/GB2159409B/en not_active Expired
- 1985-03-27 CH CH1337/85A patent/CH664285A5/de not_active IP Right Cessation
- 1985-03-28 ES ES541694A patent/ES8607728A1/es not_active Expired
- 1985-03-28 DE DE19853511307 patent/DE3511307A1/de not_active Withdrawn
- 1985-03-28 NL NL8500928A patent/NL8500928A/nl not_active Application Discontinuation
- 1985-03-28 FR FR858504647A patent/FR2561920B1/fr not_active Expired
- 1985-03-28 US US06/717,157 patent/US4650790A/en not_active Expired - Fee Related
- 1985-03-28 SE SE8501532A patent/SE8501532L/xx not_active Application Discontinuation
- 1985-03-28 LU LU85823A patent/LU85823A1/fr unknown

Also Published As

Publication number	Publication date
SE8501532D0 (sv)	1985-03-28
SE8501532L (sv)	1985-09-29
FR2561920B1 (fr)	1989-10-27
FR2561920A1 (fr)	1985-10-04
GB8508000D0 (en)	1985-05-01
ATA89485A (de)	1988-10-15
BE902010A (fr)	1985-09-25
ES541694A0 (es)	1986-06-16
CH664285A5 (de)	1988-02-29
DE3511307A1 (de)	1985-10-10
ES8607728A1 (es)	1986-06-16
GB2159409A (en)	1985-12-04
US4650790A (en)	1987-03-17
AT388100B (de)	1989-04-25
GB2159409B (en)	1988-08-10
NL8500928A (nl)	1985-10-16

Publication	Publication Date	Title
AU2014214548B2 (en)	2018-03-29	Methods of treating microbial infections, including mastitis
LU85823A1 (fr)	1986-10-06	Nouvelles combinaisons de medicaments ayant un effet synergique et procede pour les preparer
AU2012207698A1 (en)	2013-04-18	Injectable compositions for mastitis comprising an NSAID and an antibiotic in a non-aqueous solvent
RU2367433C1 (ru)	2009-09-20	Препарат для лечения мастита у коров в период лактации
RU2491921C1 (ru)	2013-09-10	Способ лечения мастита у коров в сухостойный период
AU2002319190B2 (en)	2007-01-04	Synergistic antibiotic compositions
KR100707988B1 (ko)	2007-04-16	젖소 유방염 치료 및 예방을 위한 복합항생제 조성물
JPH0656689A (ja)	1994-03-01	感染性下痢症予防及び治療用組成物
KR100375342B1 (ko)	2003-03-08	위장 질환 개선을 위한 천연 항균물질 조성물
FR2563433A1 (fr)	1985-10-31	Nouvelles compositions pharmaceutiques comprenant de l'oxytetracycline et un acide organique ayant une activite antimicrobienne et procede pour leur preparation
ES3058367T3 (es)	2026-03-10	Un compuesto antimicrobiano de ortosomicina para su uso en métodos de tratamiento de mastitis
RU2856624C1 (ru)	2026-02-24	Способ лечения при микоплазмозной пневмонии поросят
RU2847610C1 (ru)	2025-10-09	Способ лечения при стрептококковой пневмонии поросят
Vermeersch et al.	2019	Digital dermatitis in cattle: Part II: Treatment, prevention and link with other treponemal diseases
RU2524664C1 (ru)	2014-07-27	Способ профилактики массовых желудочно-кишечных и респираторных болезней молочных поросят
JPH03181421A (ja)	1991-08-07	ベータラクタム系抗生物質の作用増強剤並びに感染症予防及び治療用の医薬組成物
GB2158353A (en)	1985-11-13	Veterinary preparations
RU2593809C1 (ru)	2016-08-10	Композиционный препарат для профилактики эшерихиозного гастроэнтерита поросят
Younan	2002	Parenteral treatment of Streptococcus agalactiae mastitis in Kenyan camels (Camelus dromedarius)
FR2563432A1 (fr)	1985-10-31	Nouvelles compositions pharmaceutiques antibacteriennes et antiprotozoaires comprenant du fumarate acide de tiamuline et procede pour leur preparation
IE921419A1 (en)	1992-11-04	Treatment of mastitis
RU2646831C1 (ru)	2018-03-07	Лекарственная композиция и способ ее применения для профилактики и терапии диспепсических состояний новорожденных телят, полученных от инфицированных лейкозом коров
ES2893927T3 (es)	2022-02-10	Combinaciones de lisobactina y aminoglucósidos contra enfermedades causadas por bacterias Gram positivas y Gram negativas en animales no humanos
KR950009945B1 (ko)	1995-09-04	음료수 또는 동물사료에 첨가제로서 겐타마이신과 린코마이신의 항생제 혼합물을 함유하는 수의제제 및 이의 돼지사육에 대한 용도
CN1098076C (zh)	2003-01-08	一种治疗皮肤软组织感染及梅毒淋病的广谱抗真菌口服药品